Although the patient’s tumor PD-L1 expression and lymph node puncture PD-L1 expression were both not high at the time of surgery, referring to the relevant literature on SMARCB1-deficient tumor immunotherapy, which has shown the potential of immunotherapy for the treatment of SMARCB1-deficient tumors, we believe that the patient may still benefit from immunotherapy. This evidence concerns the gene CD274 and neoplasm.